JPMorgan Chase & Co’s Zentalis Pharmaceuticals ZNTL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $639K | Sell |
550,447
-196,029
| -26% | -$227K | ﹤0.01% | 3951 |
|
|
2025
Q1 | $1.19M | Sell |
746,476
-113,234
| -13% | -$180K | ﹤0.01% | 3566 |
|
|
2024
Q4 | $2.6M | Buy |
859,710
+370,511
| +76% | +$1.12M | ﹤0.01% | 3225 |
|
|
2024
Q3 | $1.8M | Sell |
489,199
-6,611
| -1% | -$24.3K | ﹤0.01% | 3325 |
|
|
2024
Q2 | $2.03M | Buy |
495,810
+437,189
| +746% | +$1.79M | ﹤0.01% | 3099 |
|
|
2024
Q1 | $924K | Sell |
58,621
-34,827
| -37% | -$549K | ﹤0.01% | 3622 |
|
|
2023
Q4 | $1.42M | Sell |
93,448
-8,481
| -8% | -$128K | ﹤0.01% | 3334 |
|
|
2023
Q3 | $2.04M | Sell |
101,929
-8,764
| -8% | -$176K | ﹤0.01% | 2976 |
|
|
2023
Q2 | $3.12M | Buy |
110,693
+50,092
| +83% | +$1.41M | ﹤0.01% | 2779 |
|
|
2023
Q1 | $1.04M | Buy |
60,601
+13,765
| +29% | +$237K | ﹤0.01% | 3417 |
|
|
2022
Q4 | $943K | Buy |
46,836
+4,546
| +11% | +$91.5K | ﹤0.01% | 3385 |
|
|
2022
Q3 | $916K | Sell |
42,290
-14,410
| -25% | -$312K | ﹤0.01% | 3413 |
|
|
2022
Q2 | $1.59M | Sell |
56,700
-48,879
| -46% | -$1.37M | ﹤0.01% | 3158 |
|
|
2022
Q1 | $4.87M | Buy |
105,579
+78,102
| +284% | +$3.6M | ﹤0.01% | 2581 |
|
|
2021
Q4 | $2.31M | Buy |
27,477
+2,420
| +10% | +$203K | ﹤0.01% | 3135 |
|
|
2021
Q3 | $1.67M | Buy |
25,057
+6,181
| +33% | +$412K | ﹤0.01% | 3290 |
|
|
2021
Q2 | $1M | Buy |
18,876
+4,888
| +35% | +$260K | ﹤0.01% | 3628 |
|
|
2021
Q1 | $607K | Buy |
13,988
+498
| +4% | +$21.6K | ﹤0.01% | 3944 |
|
|
2020
Q4 | $701K | Buy |
13,490
+9,193
| +214% | +$478K | ﹤0.01% | 3568 |
|
|
2020
Q3 | $144K | Buy |
4,297
+820
| +24% | +$27.5K | ﹤0.01% | 3898 |
|
|
2020
Q2 | $167K | Buy |
+3,477
| New | +$167K | ﹤0.01% | 3747 |
|